Physician profile
Patrick Reber
NPI 1033129770
$1,040.85
in general payments reported to CMS, 2019-2025
12 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.92 · 2020: $46.95 · 2021: $67.38 · 2022: $69.49 · 2023: $271 · 2024: $338 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $784.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $236.82 | 2019-2025 | Dailies Total1 |
| Bausch & Lomb Americas INC. | $236.36 | 2024 | Infuse, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $155.46 | 2019-2023 | Cequa |
| Johnson & Johnson Vision Care, INC. | $108.58 | 2025 | Acuvue |
| Apellis Pharmaceuticals, INC. | $79.26 | 2023 | Syfovre |
| Coopervision INC. | $58.01 | 2023-2025 | Misight Contact Lens, Myday Contact Lens |
| Oyster Point Pharma, INC. | $51.79 | 2023-2024 | Tyrvaya |
| Allergan, INC. | $33.30 | 2019-2020 | |
| Abbvie INC. | $24.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.18 | 2021 | |
| Lkc Technologies, INC. | $18.40 | 2024 | |
| Shire North American Group INC | $15.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Reber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.